Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dendreon
Biotech
Indapta snags $50M and signs on former Juno exec as CEO
Indapta raised more than $50 million in series A financing and has tapped former Juno Therapeutics exec Mark Frohlich, M.D., to be its new CEO.
Max Bayer
Feb 10, 2022 7:30am
Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in
Nov 10, 2017 8:14am
Chutes & Ladders—Five Prime’s COO to succeed founder as CEO
Oct 27, 2017 4:35am
Chutes & Ladders—Embattled Juno taps new R&D head
Apr 20, 2017 5:49pm
Alpine bags Nivalis, making Gold a public biotech CEO again
Apr 19, 2017 5:08am
Argos kidney cancer vax fails phase 3 futility review, future in doubt
Feb 22, 2017 8:41am
